Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) EBIT: 2014-2025

Historic EBIT for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to -$98.6 million.

  • Viking Therapeutics' EBIT fell 169.62% to -$98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.8 million, marking a year-over-year decrease of 105.15%. This contributed to the annual value of -$150.9 million for FY2024, which is 49.68% down from last year.
  • As of Q3 2025, Viking Therapeutics' EBIT stood at -$98.6 million, which was down 32.17% from -$74.6 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' EBIT registered a high of -$12.5 million during Q4 2021, and its lowest value of -$98.6 million during Q3 2025.
  • Over the past 3 years, Viking Therapeutics' median EBIT value was -$34.1 million (recorded in 2024), while the average stood at -$43.7 million.
  • Data for Viking Therapeutics' EBIT shows a maximum YoY tumbled of 169.62% (in 2025) over the last 5 years.
  • Viking Therapeutics' EBIT (Quarterly) stood at -$12.5 million in 2021, then crashed by 62.13% to -$20.3 million in 2022, then crashed by 44.38% to -$29.3 million in 2023, then slumped by 57.89% to -$46.2 million in 2024, then slumped by 169.62% to -$98.6 million in 2025.
  • Its EBIT was -$98.6 million in Q3 2025, compared to -$74.6 million in Q2 2025 and -$55.5 million in Q1 2025.